Gujarat Themis Biosyn Ltd's earnings have grown by 45.3%, whereas share price has appreciated 53.7% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.
Gujarat Themis Biosyn Ltd share price has appreciated 47% annually (CAGR) over the past ten years.
Data is not available for this company.
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.
The company has world-wide exports to satisfied customers, having customised facility for all products.
The companyâ€™s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process.
The companyâ€™s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.
Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became Indiaâ€™s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.
Business area of the company